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CRISPR/Cas9 is a relatively recent development in biotechnology that makes it simpler than 
ever before to add and remove genes from groups of cells. Most treatments currently in 
development target specific populations of somatic cells, and as such are not heritable and are 
relatively limited in their long-term effects. However, efforts to genetically modify human 
embryos have also recently taken place—if successful, these changes would affect the entire 
human cell population and be fully heritable. Such modifications introduce a host of social and 
ethical issues and lend validity to concerns that gene editing could be adapted for eugenics. This 
paper addresses the danger that germ-line editing technology poses and examines potential 
difficulties facing regulators who may hope to ameliorate its effects.  
Ultimately scientists should attempt to develop an internationally standardized agreement 
outlining what kinds of gene editing experiments are and are not permitted; until this is possible, 
they should try to achieve an informal general consensus through regular international 
conferences and encourage regulation that mirrors this consensus wherever possible. 
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Introduction 
Almost since the discovery of DNA as a heritable genetic element, scientists and 
non-scientists alike have discussed the possibility that we might one day be able to alter 
our genetic fates to suit our preference. To some, this technology holds the potential to 
herald a new era of medicine where the genetic cause of disease can be addressed before 
symptoms ever have the opportunity to manifest. Others fearfully speculated that gene 
editing would produce a reinvigoration of eugenics, and that the technology might be 
utilized to artificially reinforce pre-existing class structures and biases.  
Over the past quarter of a century, genome editing has shifted increasingly from 
the realm of science fiction to a reality. This has become particularly true with the recent 
advent of CRISPR/Cas9, a protein/RNA complex that makes altering the genetic makeup 
of cells to suit a wide variety of needs trivially simple. Early clinical trials and even a 
handful of clinic-ready treatments have made it clear that CRISPR/Cas9 is a technology 
with extraordinary therapeutic potential. However, recent attempts to use CRISPR/Cas9 
to edit the genomes of entire embryos have raised concerns about the potential long 
term social and health-related consequences that mastery of gene editing techniques 
might carry with them. Germ-line genetic changes are heritable, after all, and could have 
drastic and unforeseeable effects on future generations. 
  In this essay, I will argue that the potential ethical hazards posed by germ-line 
genome editing outweigh any potential clinical benefits it might provide. I intend to 
outline a regulatory approach through which this harm could be mitigated; although 
achieving consistent scientific regulations across national boundaries is not as 
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straightforward as it once was, efforts to do so with regards to gene editing are clearly in 
global human interests. To guide my recommendations, I will examine past and 
contemporary attempts to develop effective regulatory policies to determine how these 
approaches can be applied to the unique challenges posed by gene editing in the modern 
era. Many prospective applications of genome editing have the potential to vastly 
improve human health, however scientists and regulators must carefully weigh their 
unintended consequences in a mosaic of global regulatory environments to determine 
which are and are not worthwhile pursuits.  
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Chapter I – The Future of Gene Editing 
Clustered regularly interspaced short palindromic repeats, or CRISPRs, were first 
characterized by a group from the University of Osaka led by Yoshizumi Ishino, when he 
noticed that a bacterial DNA sequence he was studying was flanked by an unusual 
repetitive sequence1. These sequences were later discovered to have a role in the 
bacterial immune system as part of a complex, CRISPR/Cas9 that would recognize 
foreign DNA (presumably injected by viruses) and cut it into pieces which could then be 
relegated to a subcellular compartment and/or destroyed2. Because of the system’s 
ability to recognize specific DNA sequences and to produce double stranded breaks in 
precise locations, CRISPR/Cas9 quickly gained recognition as a potential tool for genome 
editing. 
Researchers developing genome editing treatments must first identify a DNA 
sequence of interest in their target cell and design a CRISPR RNA complimentary to 
some portion of that sequence. They can then introduce CRISPR-coupled Cas9 system 
into cells, where it will be directed to produce a double-stranded break onto a specific 
region of host DNA like a pair of scissors snipping through a thread3. In non-homologous 
end joining (NHEJ), this cutting action can be used to simply remove a sequence of DNA. 
This high-efficiency process usually introduces some number of random base insertions 
                                                
1 Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. "Nucleotide sequence of the 
iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, 
and identification of the gene product". Journal of Bacteriology, 1987. 
2 Mojica FJ, Díez-Villaseñor C, García-Martínez J, Soria E "Intervening sequences of 
regularly spaced prokaryotic repeats derive from foreign genetic elements". Journal of 
Molecular Evolution, 2005 
3 Marraffini, Luciano A., and Erik J. Sontheimer. "CRISPR Interference: RNA-directed 
Adaptive Immunity in Bacteria and Archaea." Nature Reviews. Genetics. March 2010. 
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or deletions between the two ends, termed “indels4.” The propensity for CRISPR/Cas9 to 
produce indels has been a major source of concern to researchers and regulator due to 
the relatively low fidelity of the system—it has the tendency to bind at off-target sites 
and then to introduce mutations into a random part of the genome. This random binding 
activity could then lead to further disease5. If coupled with the introduction of another 
DNA sequence with homologous ends, CRISPR/Cas9 can also be used to add in a new 
piece of DNA to the targeted genome using homology-directed repair (HDR)6. 
Although various treatment strategies using CRISPR/Cas9 has already been 
introduced in a number of settings, its current technical limitations—namely, issues with 
fidelity and efficiency—have somewhat reduced the number of prospective options that 
are ready for use. However, some pioneers in the field have developed treatments using 
CRISPR/Cas9 systems that are able to circumvent these limitations in some way. These 
frequently involve applying the treatment to a relatively small number of cells and 
introducing mechanisms to control cell survival and proliferation7. This helps to ensure 
that if off target mutations do occur and produce a diseased state in the selected cells, 
that the damage done is limited. Others actually take advantage of the indel-inducing 
                                                
4 Daniel P. Dever et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic 
stem cells. Nature. 2016 Nov 7 
5 Sander, J. D. & Joung, J. K. CRISPR–Cas systems for editing, regulating and targeting 
genomes. Nature Biotechnol. 32, 347–355 (2014) 
6 Chu, Van Trung. "Increasing the Efficiency of Homology-directed Repair for CRISPR-
Cas9-induced Precise Gene Editing in Mammalian Cells." Nature Biotechnology (2015 
7 Rooney, Cliona. “Current Uses of CRISPR/Cas9 in the Baylor College of Medicine 
Center for Cell and Gene Therapy.” Interview w/ Joshua Brenner, March 2017. 
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properties of cas9, intentionally damaging the functionality of target genes in an effort to 
alter protein expression8. 
The first clinical trial using CRISPR/Cas in humans began in China in October of 
2016, led by Dr. Lu You at the Sichuan Univervisty9. This trial targets multiple genes in 
mature T cells that will hopefully aid in their ability to combat cancer in late stage cancer 
patients. The treatment involves the insertion of a gene for a receptor that will allow the 
T cells to recognize an antigen, NY-ESO-1, that is commonly presented by lung cancer 
cells. Researchers will also a gene that down-regulates T cell activity called PD110.The 
former will allow T cells to target NY-ESO-1-expressing cells so that they can attack them 
directly, hopefully reducing numbers of cancer cells present in the patient; the latter 
should cause the T cells to be up regulated, improving their survivability and increasing 
their activity. Together, the modifications are expected to improve patient outcome. 
Dr. You’s group has taken a multi-faceted approach to minimize the risks 
discussed above. First, they will use a high-fidelity variant of Cas9 that will help to 
minimize off target effects. They will also perform genetic screens on the T-cells to 
determine whether or not any off-target sites have been affected, possibly inducing 
cancer-causing mutations. Finally, the protocol is only approved in patients who have 
                                                
8 Daniel P. Dever et al. “CRISPR/Cas9 β-globin gene targeting in human haematopoietic 
stem cells.” Nov 2016. 
9 Cyranoski, David. "CRISPR Gene-editing Tested in a Person for the First Time." Nature 
News. Nature Publishing Group, November 2016. 
10 Ibid 
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fewer than six months to live11. These patients have undergone all other standard 
treatments and have continued to progress in their disease. If there are unforeseen 
complications with the therapy, this final safeguard will ensure that the suffering caused 
is less grievous than if it were used in healthier people. The trial is hoped to both 
improve patient outcomes, and provide a proof-of-concept—since it is the first time that 
CRISPR/Cas9 has been used in humans, it will be useful to have evidence showing 
whether or not it works as anticipated. This is an important first step that will hopefully 
help to clear the way for the use of CRISPR treatments in people who are less seriously 
ill. 
T cell therapies using CRISPR systems are also being developed in the US, 
although they typically face slower and more onerous regulatory processes before they 
can be used in patients. A group of labs led by Dr. Cliona Rooney at Baylor College of 
Medicine is developing T cells that have been genetically modified to recognize tumor 
antigens and improve cell survivability. They also hope to include as a kind of safety 
feature to the cells, a “suicide switch.” They have used CRISPR/Cas9 to alter a gene that 
makes their modified T cells extremely vulnerable to a certain drug that should leave 
unmodified cells unaffected. As such, if there are unexpected side effects following 
administration of the cells to a patient—if the cells start attacking the wrong targets, or if 
off-target effects from the CRISPR/Cas9 treatment cause the cells to behave erratically—
                                                
11 Lu, You. PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung 
Cancer. Clinical Trials US Gov. Database. Sichuan University. November 2016. 
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clinicians can simply administer the drug and kill off the modified cells. In the near 
future, Dr. Rooney’s lab hopes to use these “CAR” (chimeric antigen receptor) T cells to 
improve survival in patients with certain types of cancer12. 
People with monogenic disorders, diseases caused by a malfunction in a single 
gene rather than by contributions from a number of genes, are excellent prospective 
candidates for CRISPR/Cas9 treatments. The best non-genetic treatments available will, 
by definition, treat only the symptoms of these disorders rather than their cause. With 
the recent improvements to gene editing brought by CRISPR/Cas9, a greater and greater 
number of researchers are looking into potential mechanisms to directly repair the 
genome of patient cells, which is a much longer term solution than currently available 
treatments.  
These monogenic diseases include conditions such as ß-thalassemia, an autosomal 
recessive genetic blood disorder in which functional ß hemoglobin subunits are not 
produced in sufficient numbers. As a result, less functional hemoglobin is present in red 
blood cells than in healthy people, meaning that their ability to deliver oxygen to organs 
and muscles is greatly reduced13. Hemoglobin diseases such as ß thalassemia are 
particularly well suited to CRISPR/Cas treatment because of the existence of γ-globin. γ-
globin is a hemoglobin chain that is normally expressed in fetuses and very young 
babies. Long before adulthood, it is repressed and replaced with ß-globin. In individuals 
                                                
12 Appendix I, Dr. Cliona Rooney, “Current Uses of CRISPR/Cas9 in the Baylor College of 
Medicine Center for Cell and Gene Therapy.” March 2017. 
13 Origa R. Beta-Thalassemia (Review Article). 2000 Sep 28, updated 2015. 
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with a faulty copy of ß-globin, this initiates the disease state14. One promising treatment 
strategy, then, would be to attempt to somehow induce a return to the expression of 
fetal hemoglobin and repression of adult hemoglobin in people with ß thalassemia, 
allowing them to produce healthy blood cells and relieving the symptoms of their 
anemia.  
A group of researchers at St. Jude, led by Dr. Elizabeth Traxler, has attempted to 
do just that. Dr. Traxler’s lab removed hematopoietic blood cells from patients with ß-
thalassemia and Sickle Cell anemia, intending to edit their genomes to cause them to 
express fetal hemoglobin. They used a variant of cas9 that is known to be very prone to 
producing random indel mutations and used it to disrupt a repressor of γ-globin 
transcription. This caused an increase in the number of γ-chain proteins present in the 
cell. This novel approach actually utilizes one of the major drawbacks of CRISPR/cas9—
its tendency to insert and delete random nucleotides at the locations where it cuts—as a 
treatment strategy.   This treatment, or one of a number of similar approaches, could 
soon be ready for use in clinical trials15. 
 
                                                
14 Edoh D, Antwi-Bosaiko C, Amuzu D. Fetal hemoglobin during infancy and in sickle cell 
adults. Afr Health Sci. 2006 
15 Elizabeth A. Traxler, et al. “A genome-editing strategy to treat β-hemoglobinopathies that 
recapitulates a mutation associated with a benign genetic condition.” Nat Med. 2016 
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Fetal globin chain expression can be induced via lentiviral vector delivery of CRISPR/Cas9 in 
hematopoietic blood cells, which are then introduced into the patient. Over time, the stem cells 
proliferate and differentiate into red blood cells with functional hemoglobin, which could 
reduce symptoms over a long period of time in patients with hemoglobin disorders like ß 
thalassemia sickle cell anemia.  
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The vast majority of research resources devoted to CRISPR/Cas9 have been aimed 
at developing treatments similar to those described above. These treatments are 
classified as “somatic cell” treatments, because they target either fully differentiated cells 
or stem cells that are not totipotent (that is, they are not able to give rise to an entire 
embryo). Such treatments target genes in a single cell type or tissue in an effort to 
restore the patient from the disease state. However, some genetic disorders affect a 
variety of cell types, cell types that are, for whatever reason, not readily accessible to 
CRISPR/cas9, or else are so deadly that by the time medical intervention using somatic 
cell gene editing treatment would be possible the damage would be done. This has raised 
interest with some groups in the possibility of directly editing human germ-line cells—
that is, cells that will develop into an embryo and eventually into every cell type in the 
body.  
 The first study to ever attempt to genetically modify human germline cells was 
carried out by a Chinese group led by Junjiu Huang published in May 2015.  His group 
used around 80 human embryos, all of which were inviable products of IVF that had 
been donated for research purposes. They used CRISPR/Cas9 to target a gene for ß-
hemoglobin, splicing out a small segment of the gene and attempting to replace it with a 
new sequence through homology dependent recombination. This approach has some 
similarity to gene editing treatments used to combat ß-thalassemia, though obviously 
these treatments occur in hematopoietic blood cells which are a somatic cell line. Huang 
et al found that fewer than half of the embryos that he had treated were missing the 
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gene segment that the CRISPR had targeted. Of these, only a small number had 
successfully incorporated the newly introduced sequence. Because the embryos were 
allowed to develop during the treatment, of those that were able to successfully splice 
out the old sequence as well as incorporate the new sequence, all were shown to be 
genetic mosaics; that is, some of the cells in the embryo had been successfully treated 
and others had not. They also found evidence of a substantial amount of off-target 
activity in these cells, with a large number of (presumably) cas9-induced indels through 
exome sequencing16.  
As Huang’s study shows, germ-line CRISPR/Cas9 treatments are far from ready 
for the clinic, unlike comparable treatments targeting somatic cells. These germ-line 
treatments carry a number of other issues as well as the technical challenges that Huang 
describes—their potential long-term health effects are completely unknown, and their 
clinical utility is questionable since genetic screening permits the selection of healthy 
embryos in any case. Developing the ability to genetically modify embryos could also 
potentially open the door to treatments with no explicit medical purposes, but rather 
intended to insert culturally desirable traits—that is, eugenics. As such, the genetic 
modification of germ-line cells is a highly controversial topic and its future in the clinic is 
far from a certainty. 
As the technology continues to develop, it seems clear that it will find new 
applications in continually broadening settings. Currently, a major limiting factor for 
when and where CRISPR/Cas treatments can be used is limited essentially by the 
                                                
16 Puping Liang, Junjiu Huang et al. “CRISPR/Cas9-mediated gene editing in human 
tripronuclear zygotes.” Protein and Cell, May 2015 
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delivery of the complex. It is necessary to actually physically remove the cells that you 
want to treat to be sure that you don’t accidentally target the wrong cells altogether, and 
so that you can screen the cells for off-target effects before you reimplant them. 
Naturally, this greatly limits the cell types you can genetically modify.  
However, this may not necessarily be the case in the future. Once CRISPR/Cas 
treatments have become better established, it’s possible that they will have such high 
fidelity and efficiency that it might not be necessary to screen cells and reimplant them 
to ensure the safety of the patient. It could eventually be possible to actually deliver the 
treatment directly into the body, perhaps using a viral vector that will only bind 
specifically to one type of cell before injecting the gene editing construct, which would 
help to ensure that only the desired tissues are affected. Somebody with Duchenne 
muscular dystrophy could then simply inject or inhale an aerosol of virus which could 
travel to every muscle cell in their body and replace the dysfunctional gene with a 
normal copy. 
As the technology becomes safer, it will also be possible to target genes that are 
not immediately life-threatening but may have some clinical benefit nonetheless. For 
example, people with certain permutations of two genes, BRCA1 and BRCA2, are 
significantly more vulnerable to developing breast cancer sometime in the future. If 
CRISPR/Cas9 becomes refined enough that it can be used in situations where the risk of 
off-target mutations would be less than the benefit of inserting another subtype of BRCA 
into cells in relevant tissues—or indeed, replacing any number of genes which may 
contribute to disease phenotypes—it could prove to be a significant boon to public 
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health. Medicine could become a highly personalized and preventative field where 
certain disease causing genes are identified and eliminated early in life in much the same 
way that people are currently vaccinated against transmissible disease. This will of 
course be limited by the safety of the treatments, which will likely never be perfect, and 
by our ability to access relevant tissues. 
Although the technology is still in many respects in its infancy, CRISPR/Cas9 is 
already showing strong promise in terms of its potential clinical applications. As new 
Cas9 variants are discovered with improved fidelity and efficiency and as new potential 
gene targets are discovered, these applications will only become more numerous. The 
labs and hospitals testing new CRISPR/Cas9 based treatments will similarly increase in 
number. Although this could prove to be a positive development in many respects, the 
low technical barrier that the use of CRISPR/Cas9 poses is something of a double edged 
sword. On the one hand, more labs working with the technique means that more 
treatments will be developed for a wider variety of illnesses. On the other, it has to be 
acknowledged that some of the labs using CRISPR/Cas9 will exist in regulatory 
environments that are less stringent than others. The dangers that a poorly designed 
gene editing treatment could pose to patients are significant. 
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Chapter II – The Evolution of Scientific Regulation 
 In the late 1960s and early 70s, the discovery and isolation of restriction 
endonucleases (viral enzymes which create double stranded breaks in DNA strands) 
allowed scientists for the first time to combine together DNA from multiple sources17.  
They could insert a target gene into a bacterial plasmid along with a selectable marker 
like ampicillin resistance, and induce a group of bacteria to absorb and replicate the 
plasmid. This product could be purified and used in future experiments. The scientific 
implications of this technology and its successors have been enormous—recombinant 
DNA is used to produce medicines including insulin and factor VIII, and to create 
genetically modified organisms for use in medicine, agriculture, and other industries. 
 Although its manifold potential uses made it a very attractive subject for 
researchers, recombinant DNA was seen as a technology with far-reaching and if 
misused, potentially devastating effects. Scientists familiar with the technology were 
worried that viruses carrying recombinant DNA could potentially introduce new genes 
into humans if proper safety measures were not taken. Equally concerning was the rising 
public concern about recombinant DNA, which was reaching a fever pitch18.  
 
                                                
 
 
17 Jackson, D.; Symons, R.; Berg, P. "Biochemical method for inserting new genetic 
information into DNA of Simian Virus 40: Circular SV40 DNA molecules containing 
lambda phage genes and the galactose operon of Escherichia coli". Proceedings of the 
National Academy of Sciences of the United States of America. 1972. 
18 Paul Berg, MF Singer. “The recombinant DNA controversy: Twenty years later.” 
Proceedings of the National Academy of Science, September 1995. 
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Members of the media and scientists alike speculated that bacteria containing 
recombinant DNA could be accidentally released into the general population, causing 
disease or even epidemics19. Many recombinant DNA experiments were performed on E. 
coli, a bacteria that commonly lives in the human gut. It is not unheard of for scientists 
working with these bacteria to become sick after accidental exposure; thus critics 
reasoned that there was a non-zero chance of recombinant DNA being released into the 
                                                
19 Judson, Horace Freeland. “Fearful of Science: Who Shall Watch the Scientists?” 
Harper's 1975 
A target gene and plasmid are both digested with matching restriction enzymes to produce “sticky 
ends.” They are then enzymatically ligated together. The recombinant plasmid can be amplified 
by growing it in competent bacterial cells, and then purified.  
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general population after such an event. They termed this “The Andromeda Scenario,” 
after the then-popular Michael Crichton novel “The Andromeda Strain,” in which 
scientists unwittingly unleash an alien microbe that nearly destroys the world20. Most 
thought this scenario unlikely, since scientists exposed to E. coli from the lab rarely pass 
it on to additional people, however the remote possibility was enough to stimulate 
concern. Still others worried that the development of recombinant DNA technology 
would lead to attempts to alter the genetic makeup of the human race through eugenics, 
                                                
20 “Recombinant DNA: Clashing Views Aired.” Science News, vol. 111, no. 12, 1977, pp. 
181–181., www.jstor.org/stable/3961707. 
  
A 1975 Harper’s Magazine article by Horace Freeland Judson that discusses concerns 
in the public and within the scientific community around recombinant DNA. 
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and wondered what the most ruthless proponents of eugenics such as Adolf Hitler might 
have done if they had access to comparable technology21. 
 In 1974, a US National Academy of Science (NAS) 
committee chaired by an influential Stanford biochemist 
named Paul recommended a temporary moratorium on any 
recombinant DNA experiments that could have dangerous 
consequences (essentially any experiments that would confer 
antibiotic resistance or potentially cancer-causing 
mutations)22. Berg decided to organize the committee after 
concerned colleagues pressured him to cease one of his own experiments, which would 
have inserted potentially pathogenic recombinant DNA into E. coli, and was believed to 
pose a biohazard risk23. Although the moratorium was heavily criticized across scientific 
communities and taken as evidence in the eyes of the press that recombinant DNA 
technology was indeed the threat that they suspected, it proved to be a successful 
measure in that it prevented potentially hazardous experiments from being performed 
before a regulatory framework existed to help with risk containment24.  
The committee also suggested that the NIH form a permanent committee to 
oversee research using recombinant DNA molecules in the future, to assess risks and 
                                                
21 Ibid 
22 Paul Berg, MF Singer. “The recombinant DNA controversy: Twenty years later.” 
Proceedings of the National Academy of Science, September 1995. 
23 Carmen, Ira H. “Cloning and the Constitution: An Inquiry into Governmental 
Policymaking and Genetic Experimentation.” University of Wisconsin Press, 1985. 
24 Paul Berg, MF Singer. “The recombinant DNA controversy: Twenty years later.” 
Proceedings of the National Academy of Science, September 1995. 
Paul Berg, 1980. NIH 
Library of Medicine. 
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determine what kinds of procedures should be taken to alleviate those risks. This 
committee was later formed as the Recombinant DNA Molecule Program Advisory 
Committee, today known as the Recombinant DNA Advisory Committee25. Despite the 
opposition, the NAS recommendation for a moratorium was respected around the world 
over the following months, even though compliance was completely voluntary. Many 
groups, Paul Berg’s included, halted any experiments using recombinant DNA molecules 
that were likely to confer carcinogenic or antibiotic resistant properties to their hosts26.  
 The committee also recommended that an international conference of experts be 
called to discuss the potential risks and benefits of recombinant DNA technology, as well 
as possible ways that any risks could be reduced or eliminated. Nine months later, in 
February of 1975, this recommendation resulted in the Asilomar conference. This 
conference constituted one of the first major efforts by the international scientific 
community to self-regulate; it was clear that failing to produce adequate regulation 
would result in likely more constrictive regulation by outside governmental forces due to 
the growing fear and ignorance surrounding recombinant DNA technology. Indeed, if the 
most fearful of the scientists were correct in their risk assessment and there was a 
disaster in which people were harmed by recombinant organisms, the subsequent 
regulation could be devastating for the field. As such, there was a concerted effort to 
develop a way to establish an estimate of risk for a given set of experiments, and to 
                                                
25 Paul Berg et al “US Summary Statement of the Asilomar Conference on Recombinant 
DNA Molecules.” National Library of Medicine. NIH, Apr. 1975 
26 Paul Berg, MF Singer. “The recombinant DNA controversy: Twenty years later.” 
Proceedings of the National Academy of Science, September 1995. 
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create guidelines to allow scientists to manage that risk without undermining their 
research.  
In developing guidelines for the use of recombinant DNA, the conference 
attempted to adhere to two major principles, “(i) that containment be made an essential 
consideration in the experimental design and, (ii) that the effectiveness of the 
containment should match, as closely as possible, the estimated risk27.” They wanted to 
ensure essentially that appropriate measures were taken to account for any potential 
dangers present without making it unduly difficult to perform the experiments necessary 
to carry the field forward. They acknowledged the limitations of their understanding, 
which were considerable in the early days of the technology, and agreed that wherever 
uncertainty was present it was better to err on the side of caution. 
The conference decided that cloning experiments using E. Coli and many other 
common bacterial models posed a minimal public health hazard, and could be safely 
performed in most labs on an open bench. This recommendation extended to vectors 
which were unlikely to survive outside of the laboratory, which could also be used with 
minimal containment. In contrast, any recombinant DNA experiments using potentially 
pathogenic vectors or targeting animals were determined to require a high degree of 
containment. Similarly, the introduction of genes that could potentially be harmful to 
humans, as well as genes that come from highly pathogenic organisms or using vectors 
that are known to infect humans, were to be deferred indefinitely. They noted that scale 
                                                
27 Paul Berg et al “US Summary Statement of the Asilomar Conference on Recombinant 
DNA Molecules.” National Library of Medicine. NIH, Apr. 1975 
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was a matter of importance, that large scale experiments required more caution than 
smaller ones due to the increased quantity of potentially dangerous material28.  
In the summary of the conference published in the Proceedings of the National 
Academy of Sciences in 1981, it is clear that the organizers expected a high level of 
cooperation from scientists and regulatory agencies around the world. They seem 
confident that their recommendations will be respected, remarking that “through both 
formal and informal channels of information within and between the nations of the 
world, the way in which potential biohazards and levels of containment are matched 
[will] be consistent29.” They state that although not every country has a regulatory body 
that has drawn up guidelines for use of recombinant DNA, scientists who find themselves 
without formal regulation should simply use the summary of the proceedings as a 
guideline.  
For its time period, this may well have been a reasonable expectation—in the 70s 
and 80s, biological and biomedical research was restricted almost entirely to North 
America and Europe. With such a small cohort of mostly westernized nations, there were 
a relatively small number of cultural, legal, and political differences to account for in 
shaping and implementing these guidelines; the scientific community was small and 
centralized enough that an agreement reached by its leaders could reliably achieve 
universal recognition. 
 Indeed, the conference was widely considered to be an outstanding success, and 
its conclusions and recommendations with regard to safety were globally respected for 
                                                
28 Ibid 
29 Ibid 
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years. As Paul Berg and Maxine Singer noted in a retrospective document published 20 
years after the Asilomar Conference, “Literally millions of experiments, many even 
inconceivable in 1975, have been carried out in the last 20 years without incident. No 
documented hazard to public health has been attributable to the applications of 
recombinant DNA technology30.” In fact, the impact of the conference went far beyond its 
initial scope and goals (which it clearly achieved beyond all expectation). It set an 
important precedent for dealing with new, potentially dangerous technologies—it was 
proof that leaders in the field could assemble, discuss the potential risks and benefits of 
the new technology, and make recommendations to formal regulatory agencies and to 
their colleagues around the world. As Berg acknowledges, their guidelines were initially 
stricter than necessary in order to safeguard against their limited understanding of 
recombinant organisms. However, the rules left plenty of room for discovery to continue, 
and were slowly relaxed as more and more was learned. The Asilomar conference 
showed that scientists were capable of regulating themselves and each other, and helped 
to reassure the public that such was the case. This capacity for self-regulation ensures 
that science can continue safely without regulation that unduly suppresses innovation. 
 
 
 
                                                
30 Paul Berg, MF Singer. “The recombinant DNA controversy: Twenty years later.” 
Proceedings of the National Academy of Science, September 1995. 
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   In contrast to the relatively small communities of the 70s and 80s, In contrast to 
There has been remarkable growth scientific output from China and India in particular over the 
past two decades. Although number of scientific publications is not necessarily the best 
measurement for productivity—in particular, it does not measure the influence or quality of these 
publications—it can at least provide some idea of the increase in scientific investment that has 
taken place in these nations. Citations per document does provide a rough metric for average 
publication quality (though this number has dropped universally over time as overall number of 
publications has increased).  
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In contrast to the relatively small communities of the 70s and 80s, contemporary 
scientific communities are no longer localized to a handful of nations. In particular31, 
China and India have developed into extremely influential and productive science hubs. 
To a lesser extent, countries like Brazil, Spain, South Korea, Iran, Turkey, and Malaysia 
have all dramatically increased their scientific output between the Asilomar conference 
and the present day in terms of total papers published. There is still a fairly substantial 
gap in terms of quality of publication output—although the raw number of papers from 
China currently rivals that of the EU, the number of papers published in high impact 
journals or receiving numerous citations has lagged behind32. Even so, the simple 
increase in raw publication numbers is indicative of increased scientific investment and 
participation from a wider variety of nations and culture, even if the quality of these 
publications on average cannot yet be said to rival that of more traditional centers for 
scientific research. 
This decentralization poses a formidable challenge to any formal or informal 
regulatory bodies seeking global cooperation on issues of research safety and ethics. 
Without entering into a discussion of moral relativism, it seems clear enough to say that 
it is more difficult to agree upon regulatory guidelines when ethical values are not 
necessarily conserved across cultures. An acceptable risk to the public in one culture may 
not be considered acceptable in another. As such, agreeing on any significant 
international framework for regulation can be extremely difficult.  
 
                                                
31 Scopus Scientific Abstract and Citation Database. Elsevier, 2017. 
32 Ibid 
 26 
Chapter III - Regulating CRISPR/Cas9 
Indeed, more recent international regulatory efforts comparable in size and scope 
to the Asilomar have faced substantially greater challenges than their predecessors. 
CRISPR/Cas9 particularly has presented a slew of potential legal and ethical hazards to 
scientists and regulators. The relatively uncontroversial modification of non-germ line 
cells using the technique is delicate enough—a major clinical misstep at this stage could 
provoke regulatory hurdles that would set the technology back years. However, in May 
of 2015 a team of Chinese scientists led by Junjiu Huang at Sun Yat-sen University 
published a study in Protein & Cell (after supposedly being rejected from higher profile 
journals due to ethics objections) describing their efforts to use CRISPR/Cas9 to 
introduce a gene into human embryos33.  Genetic modification of germ-line cells is 
explicitly illegal in many Western European nations; although it is not so in the US, the 
National Institute of Health’s Recombinant DNA Advisory Committee has announced that 
it will not approve any experiments performing such modifications34. As such, these were 
experiments that would have been impossible in the US that many found to be ethically 
outrageous35. 
Ironically, the announcement of germ-line modifications with CRISPR/cas9 came 
only shortly after a highly publicized commentary published in Nature by a group of 
leading US stem cell and regenerative medicine researchers on that very topic. Their 
commentary called for a voluntary moratorium on any research attempting to genetically 
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modify human germ cell lines36. They note that the availability of tools for genetic 
manipulation has exploded, and that it is clear that modifying embryos using zinc finger 
nucleases or CRISPR/Cas9 is possible. However, they point out from a technical 
perspective that the modification of germline cells is totally different from that of 
somatic cells. Because germline cells will eventually develop into every type of tissue in 
the body, it is much harder to predict what kinds of effects a given genetic manipulation 
will have on the health of the patient even if that manipulation is performed perfectly, 
without any unintended genetic alterations. As we know, CRISPR/Cas9 does bind at off-
target sites and induce random mutations. The effects of any such mutations in germline 
cells would likely be amplified tremendously compared to their effects in somatic cell 
treatments. As such, the patient safety issues involved in attempts at genetic modification 
of germline cells are impossible to justify. 
 The team also raise a number of ethical concerns with germ-line genetic 
experiments, noting that that “many oppose germline modification on the grounds that 
permitting even unambiguously therapeutic interventions could start us down a path 
towards non-therapeutic genetic enhancement. We share these concerns37.”In fact, the 
group argues that there is no real therapeutic justification for attempting to modify 
germline cells in the first place. In circumstances where CRISPR/Cas would be an option, 
i.e. under conditions where IVF is being employed, it is already possible to perform 
genetic screening of embryos for disease and to simply select the healthy embryos and 
discard the rest. Attempting to develop techniques to safely modify germline cells is 
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therefore unnecessary, they say, and clearly opens a door for those who would abuse the 
technique to make medically unnecessary genetic modifications. 
Finally, Lanphier and his colleagues state the need for international discussion 
and consensus. They acknowledge that germ line research is already unlikely to occur in 
the west and seem to hope that they can achieve at least temporary agreement from 
their counterparts in other parts of the world based on their concerns about the health 
risks of germline modification. If germ-line experiments are permitted to take place, they 
fear that the public will not appreciate the difference between germ-line editing and 
somatic cell editing and that there will be substantial backlash against genome editing as 
a whole. 
Huang has argued that his study demonstrates how different human embryonic 
cells are to other models like mouse embryos and human somatic cells. He says his 
results show that CRISPR/Cas9 is far from ready for use in humans, noting that “If you 
want to do it in normal embryos, you need to be close to 100% [efficiency]38.” However, 
his group implicitly supports continued efforts in this line of study, arguing that “further 
investigation of the molecular mechanisms of CRISPR/Cas9-mediated gene editing in 
human model is sorely needed[…]before any clinical application39.” This statement lends 
validity to fears that Huang’s study will prompt other groups to attempt to improve on 
his techniques. 
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 When Paul Berg called for a voluntary moratorium in the early days of 
recombinant DNA, the moratorium was accepted until such rules were developed during 
the Asilomar conference. Under similar circumstances in 2015, the moratorium 
established by Lanphier et al was broken almost immediately. Clearly then, the 
progressive decentralization of scientific research over the past several decades has had a 
very real effect on how standards of practice can be established. In the 70s, it was 
reasonable to expect cooperation from the majority of researchers if a technique was 
believed to pose a potential hazard to public health. In the present day, formal 
agreements developed by international bodies are necessary to establish clear universal 
rules. 
Although this study clearly took place well before the publication of Lanphier’s 
commentary—in fact, the commentary was written explicitly as a response to rumors 
that such studies had been performed—an article published in Nature News shortly after 
Huang’s study notes that “at least four groups in China are pursuing gene editing in 
human embryos40.” Clearly then, the recommendations of a panel of senior scientists 
based in a single nation has far less impact on the behavior of the scientific community 
as a whole than it did in the 70s. 
 In December of 2015, the National Academy of Science, the Chinese Academy of 
Science, and the Royal Academy (UK) held an international joint summit to discuss gene-
editing, including research using CRISPR/Cas9. They hoped to help develop a dialogue 
between nations with starkly different regulatory environments, to “establish norms 
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concerning acceptable uses of human germline editing and to harmonize regulations, in 
order to discourage unacceptable activities while advancing human health and 
welfare41.” The agenda included research targeting somatic cell lines, which the 
organizers (including Paul Berg) acknowledged as potentially risky but as able to be 
“appropriately and rigorously evaluated within existing and evolving regulatory 
frameworks for gene therapy[…]regulators can weigh risks and potential benefits in 
approving clinical trials and therapies42.” Germ-line editing also formed a significant 
portion of the agenda, and was framed in a much more critical light.  
The organizers note in their summary of the conference that modifying germ-line 
cells in a clinically useful way is extremely difficult due to many of the same technical 
issues raised by Lanphier et al, and subsequently confirmed by Liang et al. They also 
raise concerns about the irreversible nature of genetic changes to such cells—since germ-
line cells will develop into reproductive cells, any changes (therapeutic or otherwise) will 
be inherited by future generations. If new genes are introduced into such cells, it could 
permanently change the genetic makeup of the human race with impossible to predict 
consequences. If protocols are developed for germ-line editing, even if they are intended 
therapeutically, they could potentially be adapted by unscrupulous experimenters to 
provide non-therapeutic genetic enhancements. Since IVF is an expensive process, the 
availability of these enhancement treatments could worsen pre-existing social 
inequalities. The conference ultimately concluded that no proposed therapies have 
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demonstrated sufficient justification based on a cost/risk analysis, and that no acceptable 
legal framework currently existed to regulate such therapies. As such, they 
recommended that germ-line genome editing experiments be discouraged until the topic 
is next revisited. 
As of today, the international scientific regulatory cooperation that the organizers 
of the CRISPR conference described has not materialized. Chinese scientists in particular 
continue to perform experiments using CRISPR/Cas9 in human germ-line cells. In April 
of 2016, a group at the Guangzhou Medical University under Yong Fan published a 
report in the Journal of Assisted Reproductive Genetics in which they claimed to have 
unsuccessfully attempted to confer HIV immunity to human fetuses by inserting an allele 
called CCR5delta32 using CRISPR. They ran into many of the same issues as their 
predecessors—and included the same assurances that they knew the technology was not 
ready for the clinic—however it is clear that the development of germ-line treatments 
with CRISPR/cas9 was not halted by the recommendations of the summit on gene 
editing43.  
Faced with a lack of international cooperation, the National Academy of Science 
has made a reversal on their germ-line editing policy. Although they still acknowledge 
the dangers posed by germ-line gene editing discussed at their 2015 summit, they 
announced in February of 2017 that, pending further review, they will suspend their ban 
on such research sometime in the near future. In cases where there are no other 
therapeutic options—where the only solution would be to discard the afflicted embryos 
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altogether—they will consider accepting research studies that would attempt to repair 
these cells at the genetic level. Under these criteria, germ-line therapies could potentially 
be used for lethal genetic disorders like Huntingtons and Tay Sachs44. The clinical utility 
of such therapies is questionable, however. 
People who know that they are potential carriers of such diseases often choose to 
have in vitro fertilization, which is of course the scenario where germ-line editing would 
most likely be usable. The current protocol for such cases is to genetically screen each of 
the embryos and select those that do not carry the genetic disorder before freezing or 
discarding the rest. This method is simple, relatively inexpensive, and very effective. As 
discussed previously, germ-line editing is none of those things. Even if it is developed 
over time to the point where it can be performed with minimal risks—and this is hard to 
imagine, since the effects of germline editing will likely vary across treatments and could 
take decades or even generations to manifest themselves—it is not clear that it would 
have any clinical utility. It does not offer any advantages over the genetic screening of 
embryos and would seemingly always carry at least some nominal risk. It could 
potentially allow embryos that would otherwise have been discarded to be implanted, 
but since IVF involves the fertilization of many more embryos than are needed (this 
helps to ensure that at least a few will be viable), this too would have limited utility—if 
one embryos is not discarded, another will be. 
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Although the implications of this report are potentially disturbing, it seems to be 
based in a realistic assessment of the current status of the technology. As Alta Charo, the 
chair of the NAS Committee on Human Gene Editing states, “If we have an absolute 
prohibition in the United States with this technology advancing, it is not like it will not 
happen45.” These kinds of studies are moving forward elsewhere in the world, and will 
likely continue to do so. At least if we have them done in the United States in a 
regulatory environment that we can actually control, we can make sure that all relevant 
materials are obtained ethically, that patient safety is ensured to the highest possible 
standards, and that the results are properly scrutinized for replicability. These are ideas 
that have been driven home over the past decade by the regulatory environment 
surrounding stem cell research, which has been strict enough that many important and 
necessary studies using stem cells cannot easily be performed in the west. Instead, they 
are undertaken in regions of the world with less strict regulatory environments and often 
with less developed scientific infrastructure. 
In the west, embryonic stem cell research has been a highly political issue 
surrounded by volatility for several decades. Major research centers including Germany 
and France have long-standing bans on the creation of embryonic stem cell lines, though 
in some cases these lines can legally be imported from other countries with less strict 
regulation, such as the UK46. Since 2001, the US has taken a conservative stance towards 
stem cell research, banning the appropriation of federal funding for research creating 
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human stem cell lines without banning the creation of these lines themselves. This 
resulted for many years in the stagnation of stem cell research in these more restrictive 
nations, even during periods when some amount of funding was available; the lack of 
stability of this funding made a potentially lengthy research project an uninviting 
prospect for many. This has improved somewhat over time with the creation of several 
state and private funds specifically dedicated to stem cell research47. 
In contrast, non-western research centers like China, India, and Japan have been 
unhampered by the hang-ups affecting the US and parts of Europe, which often seem to 
be based at least partially in the religious belief that life begins at conception. In China in 
particular, stem cell research has flourished. A group led by Fiona Murray published 
findings in the New England Journal of Medicine in 2006, stating that “China is in fact 
accumulating substantial expertise in this area[…and that] China could become a major 
force in the stem-cell industry,” while acknowledging simultaneously that a lack of 
government funding and a low average wage remained a major roadblock to the 
development of a significant stem cell biotechnology industry in the country48. Murray 
also notes that because of the lack of a single centralized regulatory body comparable to 
the FDA, it is easier for a medical researcher to engage in small scale clinical trials in 
China, which could potentially provide them with an edge against competitors. Indeed, a 
2013 study by Jingyuan Luo published in PLOS One found that between 2000 and 2010 
they number of Chinese authored stem cell papers published yearly had increased 
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tenfold. Furthermore, while the quantity of stem-cell publications in the west stagnated 
or grew modestly over the same time period, the number of papers involving 
international collaborations nearly doubled, from 20.9% to 36%49. In short, the absence 
of participation from scientists in the west has helped stem cell research to flourish 
elsewhere in the world. Although many of these newer scientific centers have produced a 
large volume of high quality research, there have also been significant missteps. 
Hwang Woo-suk, a disgraced South Korean stem cell researcher, caused 
significant turmoil in his field when it was discovered amongst a litany of other ethical 
violations that his claims of having cloned embryonic human stem cells were fraudulent. 
His questionable practices first came to light in May of 2004, when a Nature article by 
David Cyranoski brought forward claims that Woo-suk had unethically and possibly 
illegally obtained human eggs for his stem cell cloning experiments50. It discussed the 
possibility that he had gone so far as to coerce one of his students, Ja Min Koo, into 
donating her eggs for the project. Even if the donation was purely voluntary, Cyranoski 
points out that the use of her egg cells was probably still unethical: 
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“The information posted with the paper states: "Neither donors nor their family, 
relatives or associates may benefit from this research." Koo, who was a co-author 
on the paper, arguably did stand to gain professionally from its publication51.” 
 
 Woo-suk eventually admitted that he had unethically sourced the eggs used in his 
studies, and was later indicted on counts of fraud and embezzlement after it became 
clear that he had falsified the data presented in the study altogether, and had stolen or 
misspent $2.6 million from federal and private donations which he initially claimed to 
have spent on his research52. As a result, he was fired from his faculty position in Seoul 
and resigned from many of his other official positions. He was ultimately convicted for 
all but the fraud offenses, receiving a 2-year prison sentence53.  
The former “Pride of Korea” cost the South Korean ministry of science and 
technology millions of dollars with his falsified studies. His status within the country 
prior to his indictment meant that he was nearly above reproach – when allegations first 
appeared, “Many commentators said it was unpatriotic to challenge someone who had 
given the country a lead in such a promising new area54.” As such, independent 
bioethicists based in Seoul who led investigations alongside Nature into Woo-suk’s 
conduct and the veracity of the published results initially faced substantial resistance 
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from his supporters55. Scientific fraud occurs all over the world—certainly the west has 
had its share of controversies and fraudulent studies—but it thrives in conditions where 
the power of an individual or institution are allowed to complicate the process of peer 
review, and where criticisms of irreproducibility are dismissed due to the prestige of the 
lab that produced the original results.  
It should be noted that in comparison to other major centers of stem cell research, 
South Korea has a relatively robust regulatory system in place. That Woo-suk’s 
corruption was discovered, exposed, and prosecuted even despite his prestigious status 
within the South Korean scientific community is testament to the quality of South Korean 
federal regulators and the national scientific regulatory environment generally. In 
regulatory environments in which fraud and unethical practices are systemic and 
widespread, it is unlikely that the discovery of such practices would produce the level of 
controversy that Woo-suk generated. This is more closely characteristic of the culture in 
some scientific fields in China than South Korea; the Chinese Food and Drug 
Administration estimated in 2016 that some 80% of 1,622 clinical trials performed in 
China contained data that was likely fabricated, or that otherwise failed to meet 
government standards56. If accurate, this report indicates a pervasive culture of scientific 
fraud that casts serious doubt on stem cell studies performed in Chinese universities. 
Because these stem cell studies were undertaken in regions which had less well-
established and rigorous regulatory environment, in many cases the studies were carried 
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out less ethically than they might have been in the west had regulations been more 
permissive. The published results may also be less reliable, which obviously poses huge 
problems to efforts to move the research forward in a clinical setting. Testing their 
reproducibility also becomes more difficult, since repeats of the basic studies might not 
be able to receive approval in the west. As such, in developing regulations for future 
technologies—particularly germ-line genome editing using CRISPR/cas9—it is important 
that guidelines do not result in complete prohibition. Keeping even-handed guidelines 
will help to ensure that studies will be performed using ethical and methodological 
standards that would be considered acceptable by the scientific community at large.  
Even so, the distinction that NAS Committee on Human Gene Editing chair Alta 
Charo draws between justified and unjustified germ-line research with her statement 
that “we are not talking about designer babies, we are talking about healthy babies” is 
flawed to a certain extent57.  She argues that clinical trials in germ line cells could be 
permitted if the science progresses to a point where it can be performed safely with a 
high degree of confidence, and “if we develop a regulatory system capable of making 
sure it is used only for those purposes, and not for anything unwarranted or untoward58.” 
The question remains whether such a regulatory system is truly possible. 
Efforts to modify non-germline cells with CRISPR are straightforward, relatively 
speaking, and have been widely undertaken. The safety issues that they pose are similar 
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to those posed by earlier gene editing techniques, and as such the regulatory framework 
necessary to monitor such treatments is already well-established. In contrast, no gene 
editing technology has yet been able to perform the successful genetic modification of 
germline cells. Obviously, no regulatory framework has yet been established to deal with 
this eventuality, and as such it is not clear how such a framework could be implemented 
effectively. Once the technology for making genetic modifications for human embryos 
exists, it will not be a trivial matter to ensure that it is used exclusively for well-tested 
clinical purposes. The NIH may hold researchers in the US to a high standard to prove 
that their treatments are safe and that they have a valid medical justification, but they 
have no way to do the same to research that occurs in other nations. If even a single 
country with a moderately sized biomedical infrastructure fails to fully regulate germ-
line modification, techniques developed in the US could potentially be adapted to ends 
that we would not consider ethically acceptable. The only way it would be even remotely 
possible to ensure that gene-editing technology developed for the clinic is not misused 
would be to develop an international agreement on what kinds of germ-line modification 
research can and cannot be conducted. Although such an agreement could prove to be 
hugely beneficial, efforts at attaining international agreement on regulatory standards in 
the past have encountered serious roadblocks. 
In November of 2015, representatives from 195 nations met for in Paris for the 
United Nations Climate Change Conference to discuss a potential international accord to 
reduce greenhouse gas emissions and thereby to combat climate change. Climate change 
is a global phenomenon that every nation contributes to. If it is allowed to continue 
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unabated, every nation also stands to face a series of economic and humanitarian crises 
of an immense magnitude. As such, there is both a considerable need and a strong 
incentive for international cooperation on taking steps to abate as much damage from 
climate change as is reasonably possible59. In apparent recognition of this fact, 194 of the 
nations in attendance signed the accord and 141 have since ratified it—far more than the 
55 parties accounting for a total of 55% of global greenhouse gas emitters required for 
the accord to go into effect. 
Implementation of the accord, however, has been weak to non-existent. This is in 
part due to the vague terms of the agreement—it does not specify a target emissions 
goals for different groups of nations, but rather permits all of them to set their own 
goals. It merely states that the overall aim of the agreement is to “keep a global 
temperature rise this century well below 2 degrees Celsius above pre-industrial levels 
and to pursue efforts to limit the temperature increase even further to 1.5 degrees 
Celsius60.” It has no provisions for punishing nations who fail to meet their own goals or 
who fail to pursue sufficiently ambitions reductions, or even to define what level of 
reduction would be considered sufficiently ambitious.  
This is problematic, since any nation that develops stricter standards for emissions 
and pursues more ambitious goals will fundamentally be at an economic disadvantage to 
nations that do not—green technology isn’t cheap, after all, and implementing it causes 
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products from the relevant region to be more expensive and therefore less competitive in 
the international market. The climate change agreement also calls for developed nations 
to raise $100 billion annually as incentive to help developing nations reduce their 
greenhouse gas emissions, partly to offset the damage that this reduction in 
competitiveness causes, but again it provides no specific framework for who should 
contribute this money or how it should be raised.  
According to the Potsdam Institute for Climate Impact Research, if every nation 
follows its proposed target emissions reductions global average temperatures will rise by 
2.7° C this century, significantly higher than the conferences 2 C° goal and nowhere near 
the stated “stretch” target of 1.5° C61. In fact, very few nations are on track to meet the 
targets that they have stated—if actual existing policies are continued, the expected 
warming will reach 3.6° C. Clearly then, despite the accord’s ambitious goal and an 
inherent global incentive to reduce climate change, signatory nations are falling far short 
of their target. 
How can we adapt the lessons learned from the Paris climate agreement to apply 
to the regulation of genome editing technologies? Clearly for any international accord to 
be successful, regulators will have to agree on specific provisions for what kind of 
research can and cannot be performed. The vague targets of the climate agreement were 
open to interpretation and resulted in vastly different regulatory behaviors within 
different nations and cultures. As such, a gene editing agreement would ideally state 
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explicitly that studies investigating how to edit the genome of germ-line cells will not be 
permitted; such studies have no clear clinical application, after all. The agreement would 
also need to set up a board responsible for ensuring that the terms are adhered to by the 
signatory parties, which in turn would require that signatories provide funding 
proportionate to their scientific investment to allow that board to function. 
The odds of such an agreement being reached are not good, for many of the same 
reasons that an equivalent agreement was not reached for climate change. Even though 
the human race as a whole would likely benefit from global cooperation on this issue, 
any nation that signed an agreement banning certain scientific practices would be at an 
economic disadvantage to any nation that did not. This prisoner’s dilemma-like scenario 
is difficult to resolve. Furthermore, although there seemed to be a tentative consensus 
among the nations leading the international gene editing conference in 2015 that germ-
line editing was not a desirable aim for the near future, studies in China have continued 
regardless62. This could indicate a difference of values between the west and east—while 
the US and EU may feel that the potential hazard to public health and risk of eugenics 
outweighs the potential economic benefits, the same may not be true elsewhere. As such, 
there may not even be the mutual desire to establish a shared set of regulations that a 
functional international accord would require. Obviously there is no way for us to 
compel other nations to adopt our moral standards, so if this is true then no effective 
international regulatory agreement can be established. 
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Even if official consensus on regulatory matters can be obtained, enforcement of 
that agreement may simply not be feasible in some regions. Particularly as certain 
technologies become cheaper and easier to perform and the barrier to entry is lowered, 
medical researchers in developing countries may find the prospective financial reward of 
these experimental procedures, coupled with the lack of regulatory enforcement, 
irresistible. As such, unless there exists the will to dedicate vast resources to 
international enforcement, even the best international regulatory agreement possible 
could prove to be ineffective. 
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Conclusions and Recommendations 
It seems unlikely that an effective and sound internationally standardized set of 
regulations for germ-line editing can be established despite the apparent hazards that the 
technology poses. Scientists in the west should focus on developing somatic cell 
treatments using CRISPR/Cas and on encouraging their counterparts in other research 
centers to do the same. International conferences like the 2015 international summit on 
gene editing should be utilized on a regular basis to help homogenize ethical standards 
amongst leaders in the field all over the world. Even if it isn’t possible to obtain formal 
regulatory agreement from major governing bodies, if a general consensus exists 
amongst scientists that experiments with germ line cells should be deferred then even 
those who are unconcerned with the social impact of their work may adhere to this 
consensus out of fear for their reputation in the eyes of their peers. 
 Regulatory policy in the US should account for the likelihood that different 
regulations will probably exist in different places. This means that we need to think 
about the possibility that germ-line genome editing treatments genuinely designed for 
clinical use could pave the way for unsafe or clinically unnecessary treatments. In other 
words, when considering a risk/benefit analysis for a proposed study, we need to 
account for the potential misapplication of the knowledge that study might produce in 
regions without strict scientific regulation. Taken with the razor-thin margin by which 
germ-line gene editing could be justified even without this consideration, it is hard to 
imagine a case in which it would be acceptable to approve research in this particular 
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field. As such, the NAS should reverse their current position (again) and refuse to 
approve any studies using CRISPR/Cas9 in the human germ line. 
We should also consider the likelihood that inconsistent regulation between 
nations could result in the development of ‘grey markets’ for both research resources 
(like the human egg cells from Woo-suk’s discredited study) and for medical procedures, 
in which members of one region where a procedure is illegal or cost-prohibitive can 
travel to another region (usually, but not necessarily, one with less medical regulatory 
infrastructure) where it is more easily accessible. This could profoundly undermine 
regulatory efforts—not only do grey markets render them ineffective at controlling 
access to the procedure in question, they may also actively encourage people to travel to 
places where a lack of regulatory oversight might result in unsafe medical treatment with 
potentially unethically sourced medical materials. The social outcome of such regulations 
can be considered in many regards worse than if more lenient rules had been 
established. Although banning germ-line research in the west outright might slow the 
development of these medical grey markets, research will slowly continue elsewhere. If 
germ-line editing eventually becomes a scientific reality, we will have to reconsider our 
prohibition against it in order to ensure that it can at least be performed in a relatively 
safe and ethical environment. 
It may not be possible to prevent the development of germ-line genome editing 
technology indefinitely, depending on how regulatory environments progress in 
emerging scientific centers. However, we should do everything in our power to slow its 
emergence—the social implications of the technology if it develops prematurely is highly 
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troubling. Hopefully, given time, scientific regulation in these newer centers will grow 
more effective and begin to reflect the concerns in the west with regards to germ-line 
gene editing.  
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Appendix I – CRISPR/Cas9 Background 
CRISPRs were first characterized by a group from the University of Osaka led by 
Yoshizumi Ishino, when he noticed that a bacterial DNA sequence he was studying was 
flanked by an unusual repetitive sequence63. However, a role for CRISPR/Cas9 in 
bacterial immune systems wasn’t fully demonstrated until 2005, when a number of 
papers were published characterizing these loci of bacterial DNA as having an apparently 
extracellular origin64. These foreign “spacer” regions were surrounded by short repetitive 
segments of DNA, as Ishino described, and were eventually determined to have mostly 
originated from bacteriophages, a type of virus that infect bacteria. They were called 
clustered regularly interspaced short palindromic repeats, or CRISPRs.  
 The CRISPR/Cas9 system interferes with this process of viral replication by 
binding to viral DNA as soon as it is injected, before it has the opportunity to incorporate 
itself into cellular DNA. One region on the CRISPR/Cas system is responsible for 
recognizing and binding a specific piece of viral DNA. Another, the nuclease region, cuts 
the DNA once it has been recognized and bound. Because of the system’s ability to 
recognize specific DNA sequences and to produce double stranded breaks in precise 
locations, CRISPR/Cas9 quickly gained recognition as a potential tool for genome 
editing.  
                                                
63 Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. "Nucleotide sequence of the 
iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, 
and identification of the gene product". Journal of Bacteriology, 1987. 
64 Mojica FJ, Díez-Villaseñor C, García-Martínez J, Soria E "Intervening sequences of 
regularly spaced prokaryotic repeats derive from foreign genetic elements". Journal of 
Molecular Evolution, 2005 
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Researchers first identify a DNA sequence of interest in their target cell and design 
a CRISPR RNA complimentary to some portion of that sequence. They can introduce 
CRISPR-coupled Cas9 system into a variety of cell types—including human cells—using 
simple techniques like electroporation, or more targeted techniques involving altered 
viruses65. Once the CRISPR/Cas9 is introduced into the cell it can be directed to produce 
a double-stranded break onto a specific region of host DNA, like a pair of scissors 
snipping through a thread66. In the simplest cases, this cutting action can be used to 
remove a sequence of DNA. If this approach is used, the cell will try to join the two cut 
ends of DNA back together by a process known as non-homologous end joining (NHEJ). 
This high-efficiency process usually introduces some number of random base insertions 
or deletions between the two ends, termed “indels67.” The propensity for CRISPR/Cas9 to 
produce indels has been a major source of concern to researchers and regulator due to 
the tendency for cas9s to bind at off-target sites—a site not completely complementary 
to its guide RNA, but similar enough that the cas9 is able to bind for an instant—and 
thereby to introduce mutations into a random part of the genome that could lead to 
further disease68. The propensity for a particular CRISPR/Cas9 combination to bind to its 
intended target over all other targets is referred to as its fidelity. 
                                                
65 Alberts, Bruce. Molecular Biology of the Cell, 5th Edition. 
66 Marraffini, Luciano A., and Erik J. Sontheimer. "CRISPR Interference: RNA-directed 
Adaptive Immunity in Bacteria and Archaea." Nature Reviews. Genetics. March 2010. 
67 Daniel P. Dever et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic 
stem cells. Nature. 2016 Nov 7 
68 Sander, J. D. & Joung, J. K. CRISPR–Cas systems for editing, regulating and targeting 
genomes. Nature Biotechnol. 32, 347–355 (2014) 
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If coupled with the introduction of another DNA sequence with homologous ends, 
CRISPR/Cas9 can also be used to add in a new piece of DNA to the targeted sequence 
using homology-directed repair (HDR). Although this process does not typically produce 
the random indels seen in NHEJ, it occurs with a much lower frequency and therefore 
the efficiency of editing using HDR is much lower (i.e. fewer cells in a treated population 
will actually have their genomes successfully edited with the desired construct)69. 
CRISPR/Cas9 treatments generally have to optimize between both fidelity and 
efficiency. As the DNA binding region is made more specific to its correct target, it often 
binds less frequently to any target whatsoever; inversely, as efficiency increases and 
more cells treated are conferred with the desired genetic alteration, the amount of off-
target activity tends to increase Various attempts at altering the nuclease to produce cas9 
variants with improved fidelity and better efficiency are underway, however until they 
are more fully resolved these issues both increase the costs associated with developing 
safe CRISPR/cas9 treatments and limit the scenarios in which those treatments can be 
used70.  
 HDR is considered to pose a somewhat lower indel risk, however the risk of off-
target activity remains. The most significant advantage that HDR holds over NHEJ is that 
it presents the opportunity to actually introduce a new gene into the genome. This not 
only makes it a potentially useful laboratory tool for producing transgenic animal 
                                                
69 Chu, Van Trung. "Increasing the Efficiency of Homology-directed Repair for CRISPR-
Cas9-induced Precise Gene Editing in Mammalian Cells." Nature Biotechnology (2015 
70 Kleinstiver, Benjamin P., and Vikram Pattanayak. "High-fidelity CRISPR–Cas9 
Nucleases with No Detectable Genome-wide Off-target Effects." Nature News. Nature 
Publishing Group, 06 Jan. 2016. Web. 01 Apr. 2017. 
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models, but also means that it could be used clinically to actually replace a 
malfunctioning gene with a functional copy, rather than simply excising the broken copy. 
This would allow function of the gene pathway to be restored and increases the number 
of diseases that CRISPR/Cas9 could potentially be used to combat. However, its low 
efficiency presents a potential problem; if the majority of cells are not affected by the 
process, clearly the therapeutic potential of the treatment is limited. Even so, efforts to 
improve the efficiency of HDR have had promising results, and ultimately the broader 
range of potential uses that accompany the ability to introduce new genes into the 
genome make HDR more attractive to many clinicians and scientists than NHEJ (though 
the latter process certainly has its uses). 
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Homology-directed repair can be induced by introducing a piece of target DNA sandwiched 
between two homologous ends—DNA regions complementary to the endogenous DNA on either 
side of the break. The cell’s repair machinery will, with low frequency, mistake the target strand as 
the endogenous strand and ligate the two together. This must occur on both sides for the repair to be 
complete. In contrast, NHEJ simply requires that the broken sequences be ligated together, but 
produces random indels.  
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Although genome editing technology has existed for decades, only with the 
advent of CRISPR/Cas9 has it been so easily accessible to so many people. CRISPR/Cas9 
distinguishes itself from older technologies in a number of ways. Its high adaptability 
and ease of use makes it particularly appealing compared to other (often higher-fidelity) 
options like zinc fingers and TALENs71. Although many treatments using these alternative 
technologies have already reached maturity, they are widely considered less promising 
than CRISPR/Cas systems due to the comparatively high cost of their development and 
the lack of ease in modifying them from one treatment to the next (although TALENs are 
somewhat cheaper to design that zinc fingers). Where Cas9 can simply be paired with a 
new guide RNA to target a new gene, an entirely new protein must be developed to 
change the DNA specificity of these other two technologies, which can be an extremely 
arduous and time-intensive process72. This ease of use and low cost barrier means that 
huge numbers of labs are able to create novel applications for the technology. In areas 
where regulatory bodies are less powerful or more lenient than others, this has resulted 
in the potential for the development of treatments with questionable ethical implications. 
 Clearly, CRISPR/Cas9 is a technology with a wide variety of potential uses. The 
ability to alter the genome at a cellular level has already shown itself to be hugely useful 
in a medical setting—treatments using TALENs and zinc finger caspases have been 
available for several years, and have seen considerable success73. A huge amount of 
                                                
71 Yeadon, Ph.D Jim. "Pros and Cons of ZNFs, TALENs, and CRISPR/Cas." The Jackson 
Laboratory. N.p., Mar. 2014.  
72 Ibid 
73 Valton, Julien et al. "A Multidrug-resistant Engineered CAR T Cell for Allogeneic 
Combination Immunotherapy". Molecular Therapy, September 2015. 
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energy has been directed towards developing the technique to improve on its current 
limitations, and it has already shown great improvement in that regard since its 
discovery. Even though it is far from fully matured as a technology compared to 
alternatives like zinc fingers or TALENs, its simplicity of use combined with its high 
degree of flexibility makes it an extremely attractive prospect for use both in the lab and 
in the clinic.  
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Appendix II—Interview with Cliona Rooney 
 
There are a number of prospective cancer treatments utilizing CRISPR/Cas9. In 
the Center for Cell and Gene Therapy at Baylor College of Medicine, Dr. Cliona Rooney’s 
lab is developing T cells that have been genetically modified to recognize tumor antigens 
and improve survivability. In the near future, they hope to use these “CAR” (chimeric 
antigen receptor) T cells to improve survival in patients with certain types of cancer. I 
spoke to Dr. Rooney about these genetically modified T cells. 
 
What are the goals of your research? 
 
I am interested in creating T cell therapies to treat cancer. Most of these T cell therapies 
have got a lot of promise, but the problem that they face when infused into patients is 
that most tumors are very immunosuppressive, and they inhibit T cell proliferation, 
function, survival etc. So, we are always looking for ways to overcome that.  
 
How do you use CRISPR/Cas9? 
 
We have several projects in progress using the CRISPR system. Previously, we were able 
to introduce genes into cells but we did not have a simple way to remove genes. There 
were some ways – you could use TALENs, or a few others, but they are much more 
complicated than CRISPR. 
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Generally speaking, our projects focus on genetically enhancing T cells for cancer 
therapies. For example, we might introduce some gene that makes the T cells function 
better in fighting cancer cells. However, there is always the concern that the T cells will 
actually function too well, that they may start attacking the wrong targets or even 
become tumorigenic themselves. To combat this possibility, one of our projects is trying 
to create a suicide switch that would be active in our genetically engineered T cells. We 
want to have some way of turning off the T cells so that we can kill them if they 
proliferate too much in the patient. That way, if they are making the patient sick we can 
quickly stop the treatment. And quite often in T cell therapies, the T cells will produce 
too many cytokines in the patient -- this increases morbidity and even mortality, so we 
would really like to have some way of switching them off.  
 
This modification also allows you to select for these T cells before you administer them 
to the patient. Since you’ve knocked out the salvage pathway, you can use a nucleoside 
analogue that will poison the salvage pathway and therefore kill off any unmodified T 
cells. Then after you infuse them, you can be sure that any cells you have administered 
will have your suicide gene in place in case it is needed. Knocking out HPRGT is one way 
we can use CRISPR/Cas in lymphocytes. 
 
How else are you using CRISPR/Cas9? 
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Dr. Max Mamonkin is planning to use T cell therapy to treat patients with acute T cell 
lymphocytic leukemia. His strategy is to use a CAR that is specific for an antigen called 
CD7 expressed on TALL cells. But the problem is that the CAR T cells themselves express 
the same protein, so as soon as you produce them they start to target and kill each other. 
So his plan is to knockout CD7 in the T-cells using CRISPR/Cas. Then he will be able to 
insert the chimeric antigen receptor specific for CD7. The result is (hopefully) T cells that 
don’t target each other, that grow and function perfectly normally, but still target TALL 
cells.  
 
What are the major advantages to using CRISPR/Cas9 over other systems 
for gene modification? 
 
There is lots of different ways to use it!  You can do it much more quickly than any of the 
other systems out there – you just design the guide RNAs and order them, and two days 
later you can do your knockout [you can excise a gene from cells]. Peggy [Margaret] 
Goodell’s lab developed this way to modify lymphocytes that’s very effective, with very 
high efficiency. You can get over 90% knockout rate with very little toxicity to the T 
cells. Sometimes there is a bit of toxicity, but not much.  
 
There is not nearly so much informatics involved, so it is also much cheaper. If we make 
a retrovirus vector to introduce a gene, we have to start with a producer cell line. If it is 
for clinical use, we have to do a huge amount of testing for all sorts of viruses, bacteria, 
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and just generally to make sure that the producer cells are exactly what we think they 
are. Just developing the producer cell line costs about a quarter of a million dollars, 
mostly because of the testing. Afterwards, you take the producer cell line and actually 
grow up the viral vector. You now have to test the vector’s effects on your cell lines, 
whether it actually has the effect that you wanted. That costs another $250,000. So to 
make a viral vector for gene modification is about $500,000. Whereas CRISPR/Cas is 
much better, all you need to do is get the protein and make your clinical grade guide 
RNAs. 
 
Don’t you also have to worry about off-target effects?  
 
We do… But you have to understand that this is different from using the system in vivo. 
We’re using them on cells outside the body, so most of the off-target toxicities will be 
evident before implantation. We can do screens to survey whether they behave 
differently from normal T cells in ways that we don’t expect, and detect other 
unintended effects that way. We make sure that they proliferate in response to antigen, 
that they don’t proliferate when there is no antigen around, that they are killing the right 
targets, etc. Even so, so the risk to the patient is not non-existent. But these patients all 
have cancer, they’ve gone through several types of chemotherapy and other treatments 
and haven’t shown much improvement. They’ll have relapsed, probably multiple times, 
or they may be refractory to any known therapy. So they are probably going to die if 
they are not treated. In that situation, you can take more risk than with a patient who is 
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quite healthy, and who otherwise might not be at risk of dying any time soon. So the risk 
is justified – it is not that great of a risk in the end, and the patients are otherwise in a 
pretty desperate situation. And that’s another reason that we want this suicide gene, so 
that if our T cells DO start behaving in unexpected ways we can halt their growth74. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                
74 Rooney, Cliona. “Current Uses of CRISPR/Cas9 in the Baylor College of Medicine 
Center for Cell and Gene Therapy.” March 2017. 
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